We performed bacteriological and clinical studies on meropenem (MEPM), a new parenteral carbapenem antibiotic, with the following results. 1. Antibacterial activity The MICs of MEPM against various clinical isolates were detemined with an inoculum size of 106 cell/ml. The MIC90 was 6.25 µg/ml for Staphylococcus aureus, 25 for Enterococcus faecalis, ≦0.05 for Escherichia coli, 0.1 for Klebsiella pneumoniae, Proteus mirabilis and Proteus vulgaris, 1.56 for Enterobacter cloacae, 3.13 for Enterobacter aerogenes, 0.39 for Serratia marcescens, 0.78 for Citrobacter freundii and, 50 for Pseudomonas aeruginosa. Its activity against gram-positive cocci was less than that of imipenem (IPM), but against gram-negative rods other than P. aeruginosa its activity was more potent than IPM, ceftazidime (CAZ) cefoperazone (CPZ), and piperacillin (PIPC). Its activity against P. aeruginosa was the same as that of IPM and CAZ, but more active than CPZ and PIPC.
|出版ステータス||出版済み - 4 1992|
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)
- Infectious Diseases
- Drug Discovery